ArticlePloS one2023
Clinical presentation, microbiology, and prognostic factors of prosthetic valve endocarditis. Lessons learned from a large prospective registry.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Prevalence of healthcare-associated infections in developing and developed countries: a systematic review.BMC infectious diseases · 2026Pooled it
- Article
- Current Surgical Approaches to Managing Infective Endocarditis With Aortic Root Abscess.Reviews in cardiovascular medicine · 2026Review
- Mitral valve abscess: echocardiographic imaging, microbiology, management, and outcomes.European heart journal. Imaging methods and practice · 2026Article
- Candida endocarditis in the United States: contemporary clinical predictors of mortality from a nationwide analysis (2016-2022).Infection · 2026Article
- Neurological Complications and Surgical Outcomes in Infective Endocarditis.Journal of the American Heart Association · 2026Article
- Infective Endocarditis in Perceval Sutureless Valves: Incidence, Diagnostic Challenges, and Management: An Expert Opinion Review.Diagnostics (Basel, Switzerland) · 2026Review
- Prosthetic-Valve Endocarditis with Discordant Isolates: A Case Report and a Review of the Literature.Infectious disease reports · 2026Article
- Clinical Profile of a Series of Left-Sided Prosthetic Valve Endocarditis: Revisiting Surgical Indications.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical and Prognostic Differences Between Mechanical Versus Biological Prosthetic Infective Endocarditis-A Nationwide Database Study.Journal of clinical medicine · 2025Article
- TNF-α inhibitor therapy and prosthetic aortic valve endocarditis: a case report.Future cardiology · 2025Article
- Clinical Outcomes of Cardiac Implantable Electronic Device-Related Endocarditis: An International ID-IRI Study.Journal of clinical medicine · 2025Article
- Advancements and Challenges in the Management of Prosthetic Valve Endocarditis: A Review.Pathogens (Basel, Switzerland) · 2024Review
- Native Infective Endocarditis: A State-of-the-Art-Review.Microorganisms · 2024Review
- Current Knowledge of Enterococcal Endocarditis: A Disease Lurking in Plain Sight of Health Providers.Pathogens (Basel, Switzerland) · 2024Review
- [Comparison of the epidemiological, clinical and diagnostic characteristics of infective endocarditis of native and prosthetic valves in a Peruvian reference center].Archivos peruanos de cardiologia y cirugia cardiovascularArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProsthetic valve endocarditis (PVE) is a serious infection associated with high mortality that often requires surgical treatment.
methodsStudy on clinical characteristics and prognosis of a large contemporary prospective cohort of prosthetic valve endocarditis (PVE) that included patients diagnosed between January 2008 and December 2020. Univariate and multivariate analysis of factors associated with in-hospital mortality was performed.
resultsThe study included 1354 cases of PVE. The median age was 71 years with an interquartile range of 62-77 years and 66.9% of the cases were male. Patients diagnosed during the first year after valve implantation (early onset) were characterized by a higher proportion of cases due to coagulase-negative staphylococci and Candida and more perivalvular complications than patients detected after the first year (late onset). In-hospital mortality of PVE in this series was 32.6%; specifically, it was 35.4% in the period 2008-2013 and 29.9% in 2014-2020 (p = 0.031). Variables associated with in-hospital mortality were: Age-adjusted Charlson comorbidity index (OR: 1.15, 95% CI: 1.08-1.23), intracardiac abscess (OR:1.78, 95% CI:1.30-2.44), acute heart failure related to PVE (OR: 3. 11, 95% CI: 2.31-4.19), acute renal failure (OR: 3.11, 95% CI:1.14-2.09), septic shock (OR: 5.56, 95% CI:3.55-8.71), persistent bacteremia (OR: 1.85, 95% CI: 1.21-2.83) and surgery indicated but not performed (OR: 2.08, 95% CI: 1.49-2.89). In-hospital mortality in patients with surgical indication according to guidelines was 31.3% in operated patients and 51.3% in non-operated patients (p<0.001). In the latter group, there were more cases of advanced age, comorbidity, hospital acquired PVE, PVE due to Staphylococcus aureus, septic shock, and stroke.
conclusionsNot performing cardiac surgery in patients with PVE and surgical indication, according to guidelines, has a significant negative effect on in-hospital mortality. Strategies to better discriminate patients who can benefit most from surgery would be desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.